Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

By G. Masters, David H. Johnson, S. Temin. Journal of oncology practice / American Society of Clinical Oncology, 2016

1,359 citations recorded by the source corpus.

Subfields: Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c8ac3f6b09ff3e6fc3b6cce906f7862e8b269926

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

Citations in the corpus

Non-small cell lung cancer: current treatment and future advances. (2016, background): “The American Society of Clinical Oncology states that treatment for a patient with a PS of 0 or 1 is a regimen of a platinum (cisplatin or carboplatin) plus paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan, or pemetrexed (34).”
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016, neutral): “Neutropenia† 22 (8) 4 (1) 31 (23) 16 (12)”
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017, methodology): “In addition, several previous versions of the ASCO guideline on the treatment of patients with stage IV NSCLC reviewed literature relevant to that population and provided concrete communication tips for clinicians, including to discuss the risks and benefits of antitumor treatment and palliative car”
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps (2016, background): “Because neutropenia carries a risk of life-threatening infections, the American Society of Clinical Oncology recommends prophylactic treatment with neutrophil-stimulating factors, including granulocyte colony-stimulating factor (G-CSF), for certain chemotherapeutic regimens (10).”
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, background): “(%)† White 101 (36) 100 (36) Asian 174 (62) 173 (62) Other 4 (1) 4 (1) Smoking status — no.”